Physician profile
Shawhin Karimi
NPI 1497174320
$29,945.70
in general payments reported to CMS, 2019-2025
74 companies · $3,667 in 2025
The $3,667 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,022 · 2020: $6,578 · 2021: $4,080 · 2022: $4,757 · 2023: $4,579 · 2024: $3,264 · 2025: $3,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,498.58 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,544.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $2,957.02 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $1,699.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,535.43 | 2019-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $1,449.89 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,444.56 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $1,320.59 | 2019-2025 | |
| Medtronic Minimed, INC. | $1,137.87 | 2019-2020 | |
| Corcept Therapeutics | $982.53 | 2019-2025 | Korlym |
| Insulet Corporation | $958.74 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $895.55 | 2019-2023 | Farxiga |
| Intuity Medical INC | $840.65 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amneal Pharmaceuticals LLC | $761.55 | 2019-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $748.12 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $713.89 | 2021-2025 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $708.62 | 2019-2025 | |
| Amarin Pharma, INC. | $628.57 | 2019-2023 | |
| Esperion Therapeutics, INC. | $586.46 | 2020-2025 | Nexletol |
| Mannkind Corporation | $516.10 | 2019-2025 | Afrezza |
| Ibsa Pharma INC. | $481.79 | 2019-2024 | Tirosint, Licart, Licart |
| Radius Health, INC. | $422.14 | 2019-2025 | Tymlos |
| Antares Pharma, INC. | $342.17 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Abbott Laboratories | $325.90 | 2019-2025 | Freestyle Libre 3 |
| Becton, Dickinson and Company | $305.81 | 2020-2022 | |
| Astellas Pharma US INC | $262.89 | 2024-2025 | Veozah |
| Alexion Pharmaceuticals, INC. | $262.54 | 2020-2025 | Strensiq |
| Zealand Pharma US, INC. | $257.95 | 2020-2021 | |
| Beta Bionics, INC. | $240.58 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $238.94 | 2022-2025 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $231.57 | 2023-2025 | Isturisa, Signifor Lar |
| Valeritas, INC. | $205.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $158.87 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $153.96 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $148.52 | 2019-2024 | Crysvita |
| Ascendis Pharma Endocrinology INC | $131.92 | 2024-2025 | Yorvipath |
| Shield Therapeutics INC | $127.89 | 2023-2024 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Vivus LLC | $118.54 | 2021-2022 | |
| Avvisto Therapeutics, LLC | $113.48 | 2025 | Cycloset |
| Medtronic, INC. | $112.12 | 2021-2023 | Minimed 780g |
| Tolmar, INC. | $111.40 | 2023-2025 | Jatenzo |
| Amphastar Pharmaceuticals, INC. | $104.30 | 2024-2025 | |
| Clarus Therapeutics INC. | $98.49 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $92.84 | 2019-2020 | |
| Kyowa Kirin, INC. | $90.54 | 2024-2025 | Crysvita |
| Amryt Pharma Holdings LTD | $79.12 | 2023 | Mycapssa |
| Neurocrine Biosciences, INC. | $78.21 | 2025 | |
| Averitas Pharma INC. | $77.77 | 2023-2025 | Qutenza |
| Shire North American Group INC | $77.69 | 2019 | |
| Pfizer INC. | $76.98 | 2019-2024 | |
| Sequel Med Tech, LLC | $75.91 | 2025 | Twiist |
| Companion Medical, INC. | $69.34 | 2019-2020 | |
| Grt US Holding, INC. | $69.02 | 2021-2022 | |
| Sandoz INC. | $62.81 | 2024-2025 | |
| Nevro Corp. | $61.60 | 2022-2024 | Senza |
| Madrigal Pharmaceuticals | $56.60 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.23 | 2022-2023 | Cycloset |
| Alvogen INC | $46.44 | 2022-2025 | Teriparatide |
| Currax Pharmaceuticals LLC | $41.70 | 2020-2024 | Contrave |
| Bigfoot Biomedical INC | $38.61 | 2022 | |
| Halozyme INC | $30.01 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $26.34 | 2025 | Imcivree |
| Gilead Sciences, INC. | $24.74 | 2019 | |
| Globus Medical, INC. | $24.19 | 2025 | Senza |
| Ipsen Biopharmaceuticals, INC | $23.38 | 2021 | |
| Lifescan, INC. | $21.86 | 2019 | |
| Embecta Corp. | $21.10 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Azurity Pharmaceuticals, INC. | $19.96 | 2024 | Azmiro |
| Verity Pharmaceuticals INC. | $17.10 | 2024 | Tlando |
| Kowa Pharmaceuticals America, INC. | $16.65 | 2020 | |
| Acella Pharmaceuticals, LLC | $16.11 | 2025 | NP Thyroid 60 |
| Acerus Pharmaceuticals Corporation | $15.36 | 2022 | |
| Glaxosmithkline, LLC. | $15.02 | 2025 | Shingrix, Arexvy |
| Arbor Pharmaceuticals, INC. | $14.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawhin Karimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.